Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
#2983 Differential TGF-β Signalling in Typical and Atypical Bronchial Carcinoids
Introduction: Typical and atypical bronchial carcinoids (TBC and ABC) are well-differentiated neuroendocrine neoplasms (NEN). Metastatic BC having low to moderate mitotic count may still be treated with somatostatin analogues and mTOR inhibitors; however, TBC and ABC have been reported to respond very differently to therapy and an effective treatment algorithm is still lacking. TGF-β is known for its ability to activate mTOR pathway and induce epithelial mesenchymal transition, affecting cell pathophysiological capabilities such as proliferation, migration and tissue invasiveness.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Borges de Souza P
Authors: Borges de Souza P, Tagliatti V, Capobianco S, Ambrosio M, Chinnici S,
Keywords: Neuroendocrine neoplasms, bronchial carcinoids, TGF-β,
Introduction: Classification of appendiceal neuroendocrine neoplasms (aNEN) changed significantly over the years and treatment algorithm remains a matter of debate.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Ribeiro S
Authors: Ribeiro S, De Maeyer F, De Man M, Carton S, Cuyle P,
Keywords: appendiceal NET, incidence in community, subtypes/WHO grade, management decisions,
Introduction: Development of carcinoid heart disease (CHD) is the major negative prognostic factor in patients with the carcinoid syndrome. The only effective treatment is valve replacement. However, the selection of candidates and determination of optimal timing remain unclear. Considerable variability in local treatment strategies exist
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Bengueddach A, Kehili H, Kaid M, Bereksi Reguig F, Bousahba A,
Keywords: carcinoid heart disease, somatostatin analogue, neuroendocrine tumors,
Introduction: Targeting the death receptor pathway of apoptosis represents a promising approach for the development of novel cancer therapeutics. TNF-related TRAIL induces apoptosis upon binding to TRAIL receptors 1 and 2 (TRAIL-R1/DR4 and TRAIL-R2/DR5). TRAIL-R3 (DcR1) and TRAIL-R4 (DcR2) have been reported to block TRAIL-mediated apoptosis upon overexpression. Specially agonists for the apoptosis-inducing TRAIL-R1 and TRAIL-R2 are currently tested in clinical trials.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Sättele R, Jann H, Fischer C, Pape U, Schefold J,
Introduction: Recent studies in pancreatic neuroendocrine tumors have identified mutations in DAXX/ATRX, MEN1, and genes involved in the phosphoinositide-3-kinase/Akt/mammalian target of rapamycin (PI3K-Akt-mTOR) pathway. However, these studies focused on abundant mutations.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Vandamme T
Authors: Vandamme T, Beyens M, Van Camp G, Boons G, Hofland L,
Keywords: pancreatic neuroendocrine tumors, PNET, genetics, tumor heterogeneity, hotspot mutations,